| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer[Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLQHLIGL peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLQHLIGL |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer, His & Avi, Human at 2μg/ml (100μl/well) on the plate can bind HLAA*02:01&B2M&PRAME TCR. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.40 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 51-58 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. |
| Synonyms |
PRAME; OIP-4; OIP4; MAPE |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
